Metabolic Disorder Therapeutics Market by Product Type, by Application, by Geography – Forecast to 2028

Report - ID613014 | 10 July, 2019 | Healthcare | 100 pages | Report Type (Global) | Publisher Name - RFM

Market Analysis Insights 
The metabolic disorder therapeutics market is expected to grow globally with an estimated CAGR 8.0% to reach USD 115.76 billion by 2028. Increasing prevalence of metabolic disorders, collaborations between manufacturers and research facilities and government initiatives are the main market drivers of this market.

 Market Segment
The Market is segmented based on Product
• Metachromatic Leukodystrophy
• Globoid Leukodystrophy
• Hepatic Encephalopathy

The Market is segmented based on Disease
• Lysosomal Storage Diseases
o Gaucher’s Disease
o Metachromatic Leukodystrophy
o Hurler - Scheie
o Sanfilipo A
o Others
• Diabetes
• Obesity
• Inherited Metabolic Disorders
• Hypercholesterolemia

The Market is segmented based on Therapy Type
• Enzyme Replacement Therapy
• Cellular Transplantation
• Small Molecule Based Therapy
• Substrate Reduction Therapy
• Gene Therapy
• Drug Therapy

The Market is segmented based on Route of Administration
• Oral
• Parenteral

The above segmentation is covered for all countries and regions listed below
• North and South America
o U.S.
o Canada
o Mexico
o Brazil
o Rest of Americas
• Europe
o Germany
o France
o U.K.
o Italy 
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o Rest of APAC
• Middle East and Africa
Competitive Research
The major players in the metabolic disorder therapeutics market are AbbVie Inc., Novo Nordisk India Pvt Ltd., Actelion Pharmaceuticals Ltd, Sanofi, Biocon, Merck Sharp & Dohme Corp., Boehringer Ingelheim International GmbH, AstraZeneca, CymaBay Therapeutics, Eli Lilly and Company
Leave a Message